Novartis Lp(a) Drug Study

[Vince]

Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD - Full Text View - ClinicalTrials.gov

• Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy
  
• Novartis is now responsible for worldwide development and commercialization of TQJ230
  
• Millions of people have elevated lipoprotein(a) (Lp(a)), an independent inherited cardiovascular disease (CVD) risk factor that cannot be effectively addressed by diet and other lifestyle changes
  
• If approved TQJ230 could be first in class treatment specifically targeting elevated Lp(a)

Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a) | Novartis